A new pill launched in the UK has the potential to transform the treatment of blood cancers, it is claimed. Currently ibrutinib, marketed as Imbruvica, can be given to patients with chronic lymphocytic leukaemia or refractory mantle cell lymphoma .

Click here to read original article